Hemel Hempstead, United Kingdom
EUSA Pharma, a subsidiary of Recordati Rare Diseases, stands at the forefront of addressing critical gaps in adult and pediatric care for cancer and rare disease patients globally. Founded in 2006, this United Kingdom-based company operates within the Biotechnology, Health Care, and Pharmaceutical sectors.
As part of the overarching Recordati group, known for its staff of over 4,300 dedicated to pharmaceutical innovation, EUSA Pharma benefits from substantial research, development, and marketing expertise. Their mission is encapsulated in the slogan: "Part of Recordati Rare Diseases, the business unit dedicated to rare diseases in the Recordati group".
Investment history includes a notable Venture Round on May 24, 2009, supported by SV Health Investors and Advent Venture Partners. This strategic investment underscores their commitment to uncovering opportunities and aiding those with limited healthcare options, reflecting their core value: "Helping the people with few or no options available is at the heart of everything we do."
Quoin Pharmaceuticals